2 recruiting, 1 active not recruiting, 1 completed, 1 terminated. 6 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 6 | Recruiting 2, Active not recruiting 1, Completed 1, Terminated 1, Withdrawn 1 |
Follow ribociclib: new trials by email Literature Review of ribociclib trials Research Report on ribociclib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt Palbocicilib, Ribociclib, Abemaciclib - Breast Cancer | Phase 4 | Completed | Beni-Suef University | 206 | 2024-08-25 | 2026-03-23 |
| Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 Genotype Palbociclib 125Mg Tab, Ribociclib 200Mg Oral Tablet, Abemaciclib 150 MG Oral Tablet - CYP3A4*22 | Phase 4 | Withdrawn | University of Michigan Rogel Cancer Center | 2024-03-01 | 2024-02-02 | |
| Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients Ribociclib - Breast Cancer, Breast Neoplasms | Phase 4 | Recruiting | Institut fuer Frauengesundheit | 1000 | 2022-10-12 | 2023-04-18 |
| Roll-over Study to Allow Continued Access to Ribociclib Ribociclib, Letrozole, Anastrozole - Metastatic Breast Cancer | Phase 4 | Active not recruiting | Novartis Pharmaceuticals | 134 | 2022-07-07 | 2026-10-19 |
| The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials Binimetinib, Encorafenib, Vemurafenib - Solid Tumors | Phase 4 | Recruiting | Pfizer | 210 | 2022-07-05 | 2026-10-19 |
| Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts Ribociclib - Breast Cancer | Phase 4 | Terminated | Georgetown University | 21 | 2021-05-20 | 2024-11-26 |
Breast Neoplasms (4)
Beni-Suef University (1) · Georgetown University (1) · Institut fuer Frauengesundheit (1) · Novartis Pharmaceuticals (1) · Pfizer (1) · University of Michigan Rogel Cancer Center (1)
United States (3) · Brazil (2) · Germany (2) · Greece (2) · Italy (2) · Portugal (2) · South Korea (2) · Spain (2) · Turkey (Türkiye) (2) · Argentina (1) · Australia (1) · Canada (1) · China (1) · Costa Rica (1) · Czechia (1)
Andreas Schneeweiss, MD, Prof. (1) · Daniel L Hertz (1) · Peter A. Fasching, MD, Prof. (1) · Sandra Swain, MD (1) · Tanja Fehm, MD, Prof. (1)
2023 (1)